Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Non-consolidated)

Overview of Results

For the cumulative second quarter period, revenue increased 8.5% year-over-year to 4,453,648 thousand yen, supported by expanded domestic demand for blood collection tube preparation devices and systems. Meanwhile, the ratio of overseas sales declined, and gross profit rose to 2,155,645 thousand yen, with operating income increasing significantly to 468,211 thousand yen. Cost control and stabilization of selling, general and administrative expenses contributed to the results. Interim net income increased 58.2% year-over-year to 321,252 thousand yen. The financial summary includes supplementary materials and a scheduled results briefing.

Shareholder Returns and Financial Stability

The equity ratio remains high at 85.4%, and attention should be paid to the announced revision to the dividend forecast (dividend increase). An increase in year-end treasury stock has affected the capital structure. Cash and cash equivalents decreased to 8,438 million yen, but operating cash flow has improved due to a decrease in accounts receivable, among other factors. Ongoing dividend policy and utilization of treasury stock will remain focal points.